Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVERS.L Regulatory News (VERS)

  • There is currently no data for VERS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

20 Nov 2019 16:33

RNS Number : 1145U
Verseon Corporation
20 November 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR").

November 20, 2019

 

Verseon Corporation

 

("Verseon" or the "Company")

 

Transaction in Own Shares, Related Party Transaction, and Update on Tender Offer

 

FREMONT, Calif.-Further to its announcements earlier today, Verseon announces that, through its wholly owned subsidiary VSH1, the Company has purchased 35,087,966 Common Shares in the Company, formerly owned by Woodford Investment Management Limited, from Link Fund Solutions Ltd ("Link") at 1.56 pence per share (the "Purchase"). The Company intends to use the share price from the Purchase as the price per share for its planned tender offer to other shareholders. Further details of the tender offer will be released as soon as practically possible.

Total Voting Rights

Following the Purchase, the issued share capital of the Company will consist of 159,737,905 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,694,988. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Related Party Transaction

Due to Link's substantial shareholding in the Company, Verseon's share purchase from Link is classified as a related party transaction under the AIM Rules for Companies. The Directors of the Company, having consulted with the Company's Nominated Adviser, Arden Partners plc, consider that the terms of the transaction are fair and reasonable insofar as the shareholders are concerned.

- Ends -

For further information, please contact:

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000

 

 

Arden Partners (NOMAD and Broker)

 

Ruari McGirr / Ciaran Walsh / Dan Gee-Summons (Corporate Finance)

 +44 (0) 20 7614 5900

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts

 

Simon Vane Percy

+44 (0) 1737 821 890

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
POSLLFFRLALIFIA
Date   Source Headline
24th Oct 20187:00 amRNSAnnouncement of 2018 Annual General Meeting
11th Oct 20187:00 amRNSBlockchain agreement with Neuseren
1st Oct 20188:59 amRNSAdditional Listing & Total Voting Rights
18th Sep 20187:00 amRNSVerseon unveils new blockchain technology
13th Sep 20187:00 amRNSVerseon commences anticoagulant phase I trial
31st Aug 20187:00 amRNSAdditional Listing & Total Voting Rights
16th Aug 20187:00 amRNSChange of Adviser
8th Aug 20187:00 amRNSInterim Results
18th Jul 20187:00 amRNSVerseon submits phase I protocol for VE-1902
6th Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
2nd Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
25th Jun 20187:00 amRNSFinal Results
14th Jun 20187:00 amRNSVerseon preparing for anticoagulant phase I trial
13th Jun 20187:03 amRNSVerseon closes US$ 22.7M mortgage
12th Jun 20187:00 amRNSAdditional Listing & Total Voting Rights
7th Jun 20187:00 amRNSVerseon presents anticoagulants at BIO 2018
2nd May 20187:00 amRNSVerseon presents DME efficacy data at ARVO 2018
18th Apr 20187:00 amRNSVerseon presents anticancer agents at AACR 2018
3rd Apr 20187:00 amRNSAdditional Listing & Total Voting Rights
5th Mar 20187:00 amRNSAdditional Listing & Total Voting Rights
10th Jan 20187:00 amRNSVerseon presents HAE program at Biotech Showcase
2nd Jan 20187:00 amRNSAdditional Listing & Total Voting Rights
15th Nov 20177:00 amRNSVerseon presents second anticoagulant candidate
14th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
8th Nov 20177:00 amRNSVerseon presents anticancer agents at BIO-Europe
8th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
20th Oct 20177:00 amRNSResult of Special Meeting & Board Appointment
2nd Oct 20177:00 amRNSVerseon presents new DME efficacy results
25th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSSpecial Shareholder Meeting & Change of Directors
22nd Sep 20177:00 amRNSVerseon closes PACE financing for its new facility
7th Aug 20177:00 amRNSAdditional Listing and Total Voting Rights
26th Jun 20177:00 amRNSVerseon presents data on DME program at BIO 2017
12th Jun 20177:00 amRNSVerseon to present drug programs at BIO 2017
6th Jun 20178:15 amRNSTransaction in Own Shares and Total Voting Rights
2nd May 20177:00 amRNSAdditional Listing & Total Voting Rights
26th Apr 20177:00 amRNSTR-1 Notification of Major Interest in Shares
26th Apr 20177:00 amRNSResult of 2017 Annual General Meeting
3rd Apr 20177:00 amRNSAnnouncement of 2017 Annual General Meeting
30th Mar 20177:00 amRNSVerseon to present anticoagulants at ACS 2017
20th Mar 20177:00 amRNSBIO-Europe Spring: Verseon presents anticoagulants
13th Mar 20177:00 amRNSFinal Results
30th Jan 20177:00 amRNSAdditional Listing & Total Voting Rights
4th Jan 20177:00 amRNSVerseon granted US patents for its inhibitors
6th Dec 20167:00 amRNSLower bleeding risk of Verseon anticoagulants
23rd Nov 20167:03 amRNSVerseon anticoagulants preserve platelet function
16th Nov 20167:00 amRNSAdditional Listing & Total Voting Rights
14th Nov 20167:00 amRNSNew anticoagulant data to be presented at AHA 2016
7th Nov 20167:00 amRNSAppointment of Corporate Brokers
31st Oct 20167:00 amRNSAdditional Listing & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.